| | Variables | Severe steatosis CAP ≥290 dB (n = 82) | No severe steatosis CAP <290 dB (n = 93) | value |
| | Age at LT, years (IQR) | 55 (50–61) | 55 (45–61) | 0.412 | | Age at TE, years (IQR) | 64 (55–69) | 60 (51–65) | 0.039 | | Donor age, years | 57 (42–68) | 59 (45–67) | 0.711 | | Male, % (n) | 71.95 (59) | 64.52 (60) | 0.374 |
| | Cause of liver disease, % (n) | | Autoimmune liver disease | 8.54 (7) | 12.90 (12) | 0.211 | | NAFLD | 1.22 (1) | (0) | | Alcoholic liver disease | 39.02 (32) | 24.73 (23) | | HCV | 3.66 (3) | 3.23 (3) | | Others | 47.56 (39) | 59.14 (55) |
| | BMI, kg/m2 (IQR) | 30.44 (26–34) | 26.51 (23–30) | 0.038 |
| | BMI category, % (n) | | Normal <25 | 26.8 (22) | 43.0 (40) | 0.045 | | Overweight 25–29.9 | 26.8 (22) | 31.2 (29) | | Obese ≥30 | 46.4 (38) | 25.8 (24) |
| | Donors BMI, kg/m2 (IQR) | 26.57 (24–29) | 26.23 (24–28) | 0.877 |
| | Donors BMI category, % (n) | | Normal <25 | 40.2 (33) | 35.5 (33) | 0.266 | | Overweight 25–29.9 | 41.5 (34) | 52.7 (49) | | Obese ≥30 | 18.3 (15) | 11.8 (11) |
| | Hypertension, % (n) | 71.95 (59) | 58.06 (54) | 0.079 | | Diabetes, % (n) | 50.00 (41) | 27.96 (26) | 0.005 | | Thrombocytes x109/L | 166 (134–218) | 170 (136–228) | 0.652 | | Glucose, mmol/L (IQR) | 6.4 (6–8) | 6 (5–7) | 0.018 | | Total bilirubin, mmol/L (IQR) | 16.5 (12–22) | 14.0 (12.22) | 0.732 | | ALT, U/L (IQR) | 29.5 (20–39) | 26.0 (18–36) | 0.056 | | AST, U/L (IQR) | 27.5 (22–43) | 28 (23–39) | 0.319 | | GGT, U/L (IQR) | 42 (24–99) | 36 (21–80) | 0.191 | | Triglyceride, mmol/L (IQR) | 1.4 (1.1–2.1) | 1.1 (0.9–1.5) | 0.004 | | Total cholesterol, mmol/L (IQR) | 5.2 (4.5–6) | 4.9 (4.4–5.6) | 0.168 | | LDL, mmol/L (IQR) | 3.1 (2.5–3.7) | 3 (2.4–3.5) | 0.340 | | HDL, mmol/L (IQR) | 1.26 (1.0–1.6) | 1.34 (1.1–1.6) | 0.227 | | CRP, mg/L (IQR) | 3.7 (2–6) | 2.5 (1–5) | 0.755 | | LSM, kPa (IQR) | 7.4 (6.3–9.2) | 6.7 (5.0–9.0) | 0.019 |
| | Immunosuppression, % (n) | | Tacrolimus | 68.3 (56) | 72.0 (67) | 0.356 | | Cyclosporine | 31.7 (26) | 28.0 (26) | | Prednisone | 1.2 (1) | 8.0 (7) | | mTOR inhibitor | (0) | 1.1 (1) | | Mycophenolate mofetil | 65.9 (54) | 72.0 (67) | | Azathioprine | (0) | 3.2 (3) |
| | Time from LT to TE, years (IQR) | 5 (3–6) | 3 (2–5) | 0.099 |
|
|
LT, liver transplantation; NAFLD, nonalcoholic fatty liver disease; HCV, hepatitis C virus infection; BMI, body mass index; AST, serum aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; LSM, liver stiffness measurement; TE, transient elastography. |
